Notably, some histologically low-grade gliomas exhibit aggressive phenotypes due to CDKN2A/B homozygous deletions or H3F3A mutations [19], while certain high-grade tumors with IDH1/2 mutations may benefit from low-intensity therapies [20]. This evidence concerns the gene CDKN2A and glioma.